CHAF1B represses TRIM13 expression by binding to its promoter. (A) CHAF1B chromatin immunoprecipitation sequencing comparing the occupancies in MOLM13, MV4;11, K562, and U937 AML cell lines. (B) Western blot at indicated timepoints after CHAF1B knockdown in U937 cells. (C,F) Taqman QPCR measuring TRIM13 expression after CHAF1B knockdown. Values shown are mean ± SD relative to SCRsh. (D) Taqman QPCR of TRIM13 expression after CHAF1B overexpression. Values shown are mean ± SD relative to those of nondoxycycline (Dox) control. (E,G) Taqman QPCR measuring TRIM13 expression after CHAF1BRRAA overexpression. Values shown are mean ± SD relative to those of non-Dox control. (H) Cell cycle assay in U937 cells expressing indicated CHAF1Bsh or CHAF1B complementary DNA for the indicated times. (± SD is omitted for simplicity) Bolded conditions are significantly different from that of control. (I) Schematic design of luciferase assay. (J) Western blot of dox-inducible CAF1 or empty vector in indicated cell lines. (K) Luciferase assay normalized for Renilla expression. Values shown are mean values from 3 biological replicates experiments. (H). ∗P < .05, as determined using one-way ANOVA with Bonferroni post hoc test (C-H) or t test with Welch correction (K).